Loading viewer...
earnings
Format: PDF earnings
Moderna's first quarter 2023 earnings presentation covering financial results, business review, and forward-looking guidance. The presentation discusses anticipated COVID-19 vaccine sales, preparations for RSV and flu vaccine launches in 2024, and clinical trial timelines for respiratory and oncology programs including individualized neoantigen therapy.
conference
25 Pages
earnings
30 Pages
Werner Enterprises
Ring Energy Q2 2024 Earnings Review
earningsearnings
43 Pages
Ring Energy, Inc.